Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March ...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 1, 2024

National Association of Black County Officials President, Miami-Dade Commissioner Kionne McGhee, Extends Warm Welcome to Fulton • BarkleyOKRP Acquires Performance Media and Marketing Technology Company Adlucent • NASA Postdoctoral Program seeks early career and senior scientists for prestigious fellowships at its locations across the U.S. • CF Industries Holdings, Inc. Reports First Quarter 2024 Net Earnings of $194 Million, Adjusted EBITDA of $459 Million • Mrs. Laura Diez Barroso and Mr. Carlos Laviada Receive the Prestigious Jeffrey Davidow Good Neighbor Award • Ouro Announces $275,000 Gift to 2024 State Teachers of the Year in Multi-Year, Multi-Million Dollar Pledge • Farmers Edge and Saskatchewan Municipal Hail Insurance Partner to Enhance Hail Business Intelligence with InsurTech Tools • New Memorandum of Understanding Leads to More Support for Communities to Manage Their Own Lands • Emergency Departments Frequently Miss Signs of Epilepsy in Children • The New Terminal One at JFK Celebrates Historic MWBE Participation During National Small Business Week • Perdoceo Education Corporation Announces First Quarter 2024 Results • Builders FirstSource Releases 2024 Corporate Social Responsibility Report • Paradox Public Relations Partners With Art Shield to Promote Next Generation of Ukrainian Artists • UGI Reports Fiscal 2024 Second Quarter Results, Concludes Strategic Review and Affirms Fiscal 2024 Guidance • In Honor of Military Appreciation Month: A Veteran's Journey of Purpose and Leadership - Transitioning from Military Service to • Phoenix Children's Unveils "Wonder And Wander," a 407-Foot Mural to Advance Hope and Healing for Patient Families • University of Massachusetts Dartmouth, a National Research University, Selects YuJa Panorama Digital Accessibility Platform to R • Parkland Reports 2024 First Quarter Results • Fisk University Announces Deborah Roberts and Al Roker as Co-Speakers for Historic 150th Commencement Ceremony • CJF Black Journalism Fellows Announced

Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

BOULDER, Colo. , March 21 /Businesswire/ - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the virtual Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 2 pm ET.

The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2I muscular dystrophies, and McArdle’s disease. The Company is also advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.